Open AccessJournal Article
Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine
Malcolm F. G. Stevens,John A. Hickman,Simon P. Langdon,David Chubb,Lisa M. Vickers,Robert Stone,Ghousia Baig,Colin Goddard,Neil W. Gibson,John Alfred Slack,Christopher Newton,Edward Lunt,Christian Fizames,François Lavelle +13 more
Reads0
Chats0
TLDR
The 3-methyl analogue, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045), was investigated further and found to possess good activity, when administered i.p. or p.o. to mice bearing the L1210 leukemia.Abstract:
A number of 3-alkyl analogues of the experimental antitumor drug mitozolomide [8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one] have been screened against murine tumors in vivo. Only the compounds with a 3-methyl- or 3-bromoethyl group possessed significant antitumor activity against the TLX5 lymphoma. The 3-methyl analogue, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045), was investigated further and found to possess good activity, when administered i.p., against the L1210 and P388 leukemias, the M5076 reticulum cell sarcoma, B16 melanoma, and ADJ/PC6A plasmacytoma. The drug was also active when administered p.o. to mice bearing the L1210 leukemia. A daily for 5 days schedule of 100 mg/kg CCRG 81045 produced increases of survival time of treated animals compared to controls of 176 and >235% against the P388 and L1210 leukemias, respectively. In the female C57BL × DBA/2 F1 mouse the 10% lethal dose was 125 mg/kg daily for 5 days. CCRG 81045 was found to undergo mild alkaline hydrolysis and ring fission to form the linear triazene 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide, which is the putative metabolite formed upon metabolic activation of the antitumor drug dacarbazine [5-(3,3-dimethyltriazen-1-yl)imidazole-4-carboxamide]. The half-life of CCRG 81045 at 37°C in 0.2 m phosphate buffer (pH 7.4) was 1.24 h, whereas that of 5-(3-methyltriazen-1-yl)imidazole-4-carbox-amide at 25°C was reported to be 8 min (F. H. Shealy and C. A. Krauth, J. Med. Chem., 9: 34–37, 1966). The half-life of CCRG 81045 in human plasma in vitro at 37°C was 0.42 h. Pharmacokinetic experiments conducted in BALB/c mice produced plasma profiles of CCRG 81045, administered i.p. or p.o., which showed a rapid absorption phase, elimination half-lives of 1.13 h (i.p.) and 1.29 h (p.o.), and a bioavailability of 0.98.read more
Citations
More filters
Journal ArticleDOI
DNA repair pathways as targets for cancer therapy
TL;DR: There is evidence that drugs that inhibit one of these pathways in such tumours could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumour cells and have fewer side effects.
Journal ArticleDOI
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Mark R. Middleton,Jean-Jacques Grob,Neil K. Aaronson,G. Fierlbeck,Wolfgang Tilgen,S. Seiter,M. E. Gore,Steinar Aamdal,Jonathan Cebon,Alan S. Coates,Brigitte Dréno,M. Henz,Dirk Schadendorf,Alexander Kapp,Jürgen Weiss,U. Fraass,P. Statkevich,Martin J. Muller,Nick Thatcher +18 more
TL;DR: Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma.
Journal ArticleDOI
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W. K. A. Yung,Robert E. Albright,Jeffrey J. Olson,R Fredericks,Karen Fink,Michael D. Prados,Michael Brada,Alexander M. Spence,Raymond J. Hohl,William R. Shapiro,Michael Glantz,Harry S. Greenberg,Robert G. Selker,Nicholas A. Vick,R. Rampling,Henry S. Friedman,Peter C. Phillips,Janet M. Bruner,N. Yue,David Osoba,S Zaknoen,Victor A. Levin +21 more
TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Journal ArticleDOI
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
Edward S. Newlands,Malcolm F. G. Stevens,Stephen R. Wedge,Richard T. Wheelhouse,Cathryn S Brock +4 more
TL;DR: This poster presents a poster presented at the 2016 American Academy of Medical Oncology Congress on Wednesday, 3 March 2016 calling for awareness of the importance of informed consent in the selection of patients for cancer treatment.
Journal Article
Temozolomide and treatment of malignant glioma.
TL;DR: Predictable bioavailability and minimal toxicity make temozolomide a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more